Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 9/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20221841 | 1.00 | RIPK1 (0.46) | RIPK1LMNAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL25587583 | 1.00 | RIPK1 (0.46) | RIPK1LMNAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL20469393 | 1.00 | RIPK1 (0.46) | RIPK1LMNAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL20469411 | 1.00 | RIPK1 (0.46) | RIPK1LMNAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL25594207 | 0.83 | RIPK1 (0.46) | RIPK1LMNADPP4CYP2C19HSD17B10 | |
| SCHEMBL25591737 | 0.83 | RIPK1 (0.46) | RIPK1LMNADPP4CYP2C19HSD17B10 | |
| SCHEMBL20469348 | 0.83 | RIPK1 (0.46) | RIPK1LMNADPP4CYP2C19HSD17B10 | |
| SCHEMBL25591736 | 0.83 | RIPK1 (0.46) | RIPK1LMNADPP4CYP2C19HSD17B10 | |
| SCHEMBL28534805 | 0.80 | RIPK1 (0.44) | RIPK1LMNADPP4CYP2C19HSD17B10 | |
| SCHEMBL28534808 | 0.80 | RIPK1 (0.44) | RIPK1LMNADPP4CYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20180222876-A1 | VINYL FLUORIDE CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222876-A1 | VINYL FLUORIDE CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | RIPK1 3101/4885LMNA 3987/4885ALDH1A1 1466/4885 |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | YAP1, TERF2IP, TEAD1 | RIPK1 595/4885LMNA 1845/4885ALDH1A1 3813/4885 |
| US-20230174538-A1 | Tricyclic heterocycles | YAP1, TEAD1, TERF2IP | RIPK1 639/4885LMNA 2014/4885ALDH1A1 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.